The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia
Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia
Sponsor: Bristol-Myers Squibb
Terminated
difficulty with technical aspect of fMRI, resources to complete the study ran out
Other terminated trials from Bristol-Myers Squibb
Other Schizophrenia trials with similar outcome
Listed as NCT00209027, this NA trial focuses on Schizophrenia and remains terminated or withdrawn. Sponsored by Bristol-Myers Squibb, it has been updated 6 times since 2005, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Dec 2021 — Jul 2024 [monthly]
Terminated NA
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated NA
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Emory University
For direct contact, visit the study record on ClinicalTrials.gov .